ASCO GI 2023 Conference Coverage
Playback speed
10 seconds
ASCO GI 2023 INTEGRATE IIa Randomised, Double-Blind, Phase III Study: Regorafenib vs. Placebo in Refractory Advanced Gastro-Esophageal Cancer
By
ASCO GI 2023 Conference Coverage
FEATURING
Nick Pavlakis
By
ASCO GI 2023 Conference Coverage
FEATURING
Nick Pavlakis
137 views
February 23, 2023
Login to view comments.
Click here to Login
Videos